Interestingly, some synthetic (these mutations have not been identified in cancer patients as of yet) constitutively activating ERBB4 mutations, such Q646C and I658E, have been demonstrated not to promote growth (81), or even promote apoptosis (82), in vitro. This evidence concerns the gene ERBB4 and cancer.